Retinoid-X receptor (RXR)- and retinoic acid receptor (RAR)-mediated signaling is induced by retinoic acids (RA), which are involved in the regulation of skin permeability, differentiation and immune response. Dysregulation of retinoid signaling is present in various skin disorders. Topically and systemically administered synthetic RAR or RXR agonists might influence retinoid-mediated signaling in the skin of RARE reporter animals and gene expression analysis for retinoid, skin homeostasis and skin inflammation marker genes and local retinoid concentrations. Mice were treated orally and topically with synthetic ligands and bioimaging, QRT-PCR and retinoid analysis were performed. Topical application of the synthetic RAR ligand AM580 significantly enhanced retinoid signaling in skin while topical application of the RXR ligand LG268 did not influence retinoic acid receptor re-sponse elements (RARE)-mediated signaling. Systemic treatments with LG268 decreased the expression of genes involved in skin homeostasis, RA synthesis and skin RA concentrations, while it increased various markers for skin inflammation and RA degradation, which corresponds to decreased skin RARE signaling. We conclude from these observations that increased systemic concentrations of an RXR -ligand may be one reason for reduced retinoid signaling, -reduced all-trans RA levels in the skin, reduced epidermal homeostasis and increased skin inflammation marker expression with potential relevance for various skin disorders, like atopic dermatitis.

Keywords:
Retinoid-X receptor ligand, Retinoids, Skin disorder
1.
Reichrath J, Lehmann B, Carlberg C, Varani J, Zouboulis CC: Vitamins as hormones. Horm Metab Res 2007;39:71-84.
2.
Rühl R: Effects of dietary retinoids and carotenoids on immune development. Proc Nutr Soc 2007;66:458-469.
3.
Elias PM: Retinoid effects on the epidermis. Dermatologica 1987;175(suppl 1):28-36.
4.
Zouboulis CC, Xia L, Akamatsu H, Seltmann H, Fritsch M, Hornemann S, Rühl R, Chen W, Nau H, Orfanos CE: The human sebocyte culture model provides new insights into development and management of seborrhoea and acne. Dermatology 1998;196:21-31.
5.
Stephensen CB, Rasooly R, Jiang X, Ceddia MA, Weaver CT, Chandraratna RA Bucy RP: Vitamin A enhances in vitro Th2 development via retinoid X receptor pathway. J Immunol 2002;168:4495-4503.
6.
Trautmann A, Akdis M, Blaser K, Akdis CA: Role of dysregulated apoptosis in atopic dermatitis. Apoptosis 2000;5:425-429.
7.
Wiedermann U, Tarkowski A, Bremell T, Hanson LA, Kahu H, Dahlgren UI: Vitamin A deficiency predisposes to Staphylococcus aureus infection. Infect Immun 1996;64:209-214.
8.
Zouboulis CC: Retinoids - which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol 2001;14:303-315.
9.
Mihály J, Gamlieli A, Worm M, Rühl R: Decreased retinoid concentration and retinoid signalling pathways in human atopic dermatitis. Exp Dermatol 2011;20:326-330.
10.
Spilianakis CG, Lee GR, Flavell RA: Twisting the Th1/Th2 immune response via the retinoid X receptor: lessons from a genetic approach. Eur J Immunol 2005;35:3400-3404.
11.
Nunez V, Alameda D, Rico D, Mota R, Gonzalo P, Cedenilla M, Fischer T, Bosca L, Glass CK, Arroyo AG and Ricote M: Retinoid X receptor alpha controls innate inflammatory responses through the up-regulation of chemokine expression. Proc Natl Acad Sci USA 2010;107:10626-10631.
12.
Li M, Messaddeq N, Teletin M, Pasquali JL, Metzger D, Chambon P: Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci USA 2005;102:14795-14800.
13.
Singh VK, Mehrotra S, Agarwal SS: The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999;20:147-161.
14.
Uchida T, Suto H, Ra C, Ogawa H, Kobata T, Okumura K: Preferential expression of T(h)2-type chemokine and its receptor in atopic dermatitis. Int Immunol 2002;14:1431-1438.
15.
Svensson M, Johansson-Lindbom B, Zapata F, Jaensson E, Austenaa LM, Blomhoff R, Agace WW: Retinoic acid receptor signaling levels and antigen dose regulate gut homing receptor expression on CD8+ T cells. Mucosal Immunol 2008;1:38-48.
16.
Ebihara K, Carlsen H, Kuwata N, Aydemir G, Rühl R, Blomhoff R: A novel transgenic reporter mouse model for in vivo assessment of retinoic acid receptor transcriptional activation. Submitted.
17.
Rühl R: Method to determine 4-oxo-retinoic acids, retinoic acids and retinol in serum and cell extracts by liquid chromatography/diode-array detection atmospheric pressure chemical ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 2006;20:2497-2504.
18.
Andoh T, Nishikawa Y, Yamaguchi-Miyamoto T, Nojima H, Narumiya S, Kuraishi Y: Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. J Invest Dermatol 2007;127:2042-2047.
19.
Kuraishi Y, Ohtsuka E, Nakano T, Kawai S, Andoh T, Nojima H, Kamimura K: Possible involvement of 5-lipoxygenase metabolite in itch-associated response of mosquito allergy in mice. J Pharmacol Sci 2007;105:41-47.
20.
Kim HJ, Kim DK, Kim H, Koh JY, Kim KM, Noh MS, Lee S, Kim S, Park SH, Kim JJ, Kim SY, Lee CH: Involvement of the BLT2 receptor in the itch-associated scratching induced by 12-(S)-lipoxygenase products in ICR mice. Br J Pharmacol 2008;154:1073-1078.
21.
Amann PM, Schadendorf D, Owen RW, Korn B, Eichmuller SB, Bazhin AV: Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line -HaCaT. Exp Dermatol 2011;20:373-375.
22.
Virtanen M, Sirsjo A, Vahlquist A, Torma H: Keratins 2 and 4/13 in reconstituted human skin are reciprocally regulated by retinoids binding to nuclear receptor RARalpha. Exp Dermatol 2010;19:674-681.
23.
Fisher GJ, Voorhees JJ: Molecular mechanisms of retinoid actions in skin. FASEB J 1996;10:1002-1013.
24.
Schuster GU, Kenyon NJ, Stephensen CB: Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthma. J Immunol 2008;180:1834-1842.
25.
Allenby G, Bocquel MT, Saunders M, Kaz-mer S, Speck J, Rosenberger M, Lovey A, Kastner P, Grippo JF, Chambon P, et al: Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci USA 1993;90:30-34.
26.
Sakhi AK, Gundersen TE, Ulven SM, Blomhoff R, Lundanes E: Quantitative determination of endogenous retinoids in mouse embryos by high-performance liquid chromatography with on-line solid-phase extraction, column switching and electrochemical detection. J Chromatogr A 1998;828:451-460.
27.
Ulven SM, Gundersen TE, Sakhi AK, Glover JC, Blomhoff R: Quantitative axial profiles of retinoic acid in the embryonic mouse spinal cord: 9-cis retinoic acid only detected after all-trans-retinoic acid levels are super-elevated experimentally. Dev Dyn 2001;222:341-353.
28.
Kane MA, Chen N, Sparks S, Napoli JL: Quantification of endogenous retinoic acid in limited biological samples by LC/MS/MS. Biochem J 2005;388:363-369.
29.
Gundersen TE, Bastani NE, Blomhoff R: Quantitative high-throughput determination of endogenous retinoids in human -plasma using triple-stage liquid chroma-tography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:1176-1186.
30.
Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS: Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes. Carcinogenesis 2003;24:1541-1548.
31.
Egea PF, Mitschler A, Moras D: Molecular recognition of agonist ligands by RXRs. Mol Endocrinol 2002;16:987-997.
32.
de Urquiza AM, Liu S, Sjoberg M, Zetterstrom RH, Griffiths W, Sjovall J, Perlmann T: Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000;290:2140-2144.
33.
Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 1995;83:841-850.
34.
Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-954.
35.
Grenningloh R, Gho A, di Lucia P, Klaus M, Bollag W, Ho IC, Sinigaglia F, Panina-Bordignon P: Cutting Edge: Inhibition of the retinoid X receptor (RXR) blocks T helper 2 differentiation and prevents allergic lung inflammation. J Immunol 2006;176:5161-5166.
36.
Li M, Hener P, Zhang Z, Kato S, Metzger D, Chambon P: Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 2006;103:11736-11741.
37.
Andoh T, Nishikawa Y, Yamaguchi-Miyamoto T, Nojima H, Narumiya S, Kuraishi Y: Thromboxane A(2) induces itch-associated responses through TP receptors in the skin in mice. J Invest Dermatol 2007;127:2042-2047.
38.
Fallon PG, Sasaki T, Sandilands A, Campbell LE, Saunders SP, Mangan NE, Callanan JJ, Kawasaki H, Shiohama A, Kubo A, Sundberg JP, Presland RB, Fleckman P, Shimizu N, Kudoh J, Irvine AD, Amagai M, McLean WH: A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet 2009;41:602-608.
39.
Stephensen CB, Borowsky AD, Lloyd KC: Disruption of Rxra gene in thymocytes and T lymphocytes modestly alters lymphocyte frequencies, proliferation, survival and T helper type 1/type 2 balance. Immunology 2007;121:484-498.
40.
Grun F, Blumberg B: Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. Rev Endocr Metab Disord 2007;8:161-171.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.